-The Indian Express At a time when the government is struggling to get past objections from its coalition partners to attract investment in certain sectors such as retail, aviation and pensions fund management, a grim internecine ministerial battle has applied the brakes on foreign direct investment flow into one of the more attractive and lucrative sectors — pharmaceuticals. Clearances for over Rs 1,000 crore FDI in this sector, the second largest in...

-The Business Standard State must get out of insulin price-setting The National Pharmaceutical Pricing Authority, or NPPA, has turned down the request of drug companies to raise insulin prices. Domestic insulin-makers Biocon and Cadila had argued that the cost of production and packaging had become higher, and multinational corporation Eli Lilly wanted the depreciation in the rupee vis-à-vis the dollar to be factored into the price. The NPPA says it has...

-Live Mint Natco Pharma Ltd, which has started selling a generic version of Bayer AG’s patented cancer treatment Nexavar in India at a fraction of the price charged by the German firm, plans to use the so-called compulsory licensing route to try and win the right to copy more patented drugs, said vice-chairman and chief executive officer Rajeev Nannapaneni. The Hyderabad-based company has already identified the patented drugs for which it will...

-The New York Times India's coalition government just celebrated the third anniversary of its tenure with a self-congratulatory banquet that could not have been more poorly timed: India's currency, the rupee, is falling; investment is down; inflation is rising; and deficits are eating away at government coffers. While short-term growth has slowed but not ground to a halt, India's problems have dampened hopes that it, along with China and other non-Western economies,...

It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....